TA312 | Search results | NICE

Showing 1 result for ta312

Sort by

Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)
Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.
Result type
Technology appraisal guidance
Last updated
17 March 2020
View recommendations for TA312
Show all sections
Sections for TA312